StemRIM Inc. Logo

StemRIM Inc.

Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.

4599 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ7丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

StemRIM Inc. is a biotechnology company engaged in the research and development of a next-generation class of regenerative medicine called "Regeneration-Inducing Medicine™". Originating as a venture from Osaka University, the company focuses on developing drugs with a novel mechanism of action. This approach aims to maximize the body's innate ability to repair itself by recruiting a patient's own in-vivo stem cells to damaged tissues, thereby inducing functional regeneration without conventional cell-therapy. The company's drug development pipelines target intractable diseases.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for StemRIM Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 05:32
Regulatory News Service
訂正臨時報告書
Japanese 30.7 KB
2025-03-13 04:31
Report Publication Announcement
確認書
Japanese 8.0 KB
2025-03-13 04:30
Interim Report
半期報告書-第20期(2024/08/01-2025/07/31)
Japanese 228.6 KB
2024-11-25 08:13
Registration Form
有価証券届出書(参照方式)
Japanese 49.5 KB
2024-11-18 01:31
Share Issue/Capital Change
訂正臨時報告書
Japanese 32.6 KB
2024-11-13 08:10
Regulatory News Service
臨時報告書
Japanese 36.2 KB
2024-10-31 05:28
Post-Annual General Meeting Information
臨時報告書
Japanese 22.4 KB
2024-10-31 03:35
Governance Information
内部統制報告書-第19期(2023/08/01-2024/07/31)
Japanese 21.0 KB
2024-10-31 03:35
Registration Form
確認書
Japanese 8.1 KB
2024-10-31 03:32
Annual Report
有価証券報告書-第19期(2023/08/01-2024/07/31)
Japanese 2.7 MB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.7 KB
2024-07-26 08:53
Regulatory News Service
臨時報告書
Japanese 35.8 KB
2024-07-25 02:46
Regulatory News Service
臨時報告書
Japanese 21.7 KB
2024-06-13 02:57
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-13 02:56
Quarterly Report
四半期報告書-第19期第3四半期(2024/02/01-2024/04/30)
Japanese 166.9 KB

Automate Your Workflow. Get a real-time feed of all StemRIM Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for StemRIM Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SEOUL PHARMA CO.,LTD Logo
Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.
South Korea 018680
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea 378800
Shedir Pharma Group Logo
Develops and sells pharmaceutical, nutraceutical, and dermo-cosmetic products in Italy & Spain.
Italy SHE
SHIELD THERAPEUTICS PLC Logo
Commercializing a novel oral therapy for adults with iron deficiency.
United Kingdom STX
SHINPOONG PHARMACEUTICAL CO.,LTD Logo
R&D-driven pharma firm making APIs, finished drugs, and medical products for global markets.
South Korea 019170
Shionogi & Co.,Ltd. Logo
A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.
Japan 4507
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030

Talk to a Data Expert

Have a question? We'll get back to you promptly.